MBIO

Mustang BioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$0.50

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.25

Analysis reference price unavailable

Analysis 2026-05-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-15

AI commentary

Primary-source evidence is solid because the April 17, 2026 8-K and May 5, 2026 10-Q are available, but post-earnings interpretation is still thin. The market reaction was weak after the Q1 filing: MBIO closed at $0.77 on May 5, 2026, then drifted to $0.66 by May 12, 2026 and $0.63 by May 14, 2026, suggesting the market focused more on listing/dilution constraints than on the lower burn profile. The added long-horizon financing catalyst remains cautious because it depends on runway execution and capital access rather than a confirmed partnership, pivotal trial, or approved product. Fresh analyst revision and target-change coverage was not available in checked sources, so this remains a low-coverage monitoring memo rather than a high-conviction call.

RankAlpha Sentiment Codex - 2026-05-15

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-Q1 2026 filing digestion centers on runway rather than revenue upsideHigh impact

The Q1 2026 10-Q showed cash and cash equivalents of $16.3 million at March 31, 2026, a Q1 net loss of about $1.0 million, and management stating cash is sufficient for at least twelve months from issuance of the financial statements; this is the key post-earnings support point because no separate Q1 2026 earnings release is listed on the company IR financial-results page as of May 15, 2026. [#10-Q-2026-05-05]

2026-09-30eventMB-109 investigator-sponsored study timing is the main clinical forward hookHigh impact

Mustang said it is exploring with City of Hope and Nationwide the possibility of initiating an investigator-sponsored single-institution MB-109 study in the third quarter of 2026 after prior MB-101 and MB-108 Phase 1 treatment phases completed; confirmation of study initiation would be the clearest program-specific upside catalyst from here. [#10-Q-2026-05-05]

2026-10-12catalystCapital structure and listing remediation remain dominant overhangsHigh impact

The company is below Nasdaq's $1.00 minimum bid requirement, with a cure deadline of October 12, 2026, and its 10-Q says it is subject to Form S-3 baby-shelf limits, constraining primary capital raising flexibility; if MBIO cannot regain compliance organically, reverse-split and dilution risk remain central to the thesis. [#8-K-2026-04-17] [#10-Q-2026-05-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-15 • Updated nightlySource: Internal modelMethodology